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Background and the purpose of the study: Blood contact with artificial surfaces of the extracorporeal circuit and
ischemia-reperfusion injury in CABG with CPB, may lead to a systemic inflammatory response. Hypertonic saline
have been recently investigated as a fluid in order to decrease inflammatory response and cytokines generation in
patients undergo cardiac operations. Our purpose is to study the prophylactic effect of HS 5% infusion versus NS
on serum IL-6 as an inflammatory & IL-10 as an anti-inflammatory biomarker in CABG patients.
Methods: The present study is a randomized double-blinded clinical trial. 40 patients undergoing CABG were
randomized to receive HS 5% or NS before operation. Blood samples were obtained after receiving HS or NS, just
before operation, 24 and 48 hours post-operatively. Plasma levels of IL-6 and IL-10 were measured by ELISA.
Results and major conclusion: Patients received HS had lower levels of IL-6 and higher level of IL-10 compared
with NS group, however these differences were not statistically significant. Results of this study suggest that
pre-treatment with small volume hypertonic saline 5% may have beneficial effects on inflammatory response
following CABG operation.
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Infusion of Hypertonic saline (HS) solution increases
serum osmolarity and markedly intravascular and inter-
stitial fluid volume expansion, which causes improving
hemodynamic status [1]. Fluid resuscitation with various
concentrations of HS solutions (1.8% - 7.5%) has been
investigated in different types of hypovolemic shock [1];
pre-operative, intra-operative and post-operative fluid
therapy [2], burn injury and also septic shock [1]. HS is
inexpensive and has no risk of anaphylactoid reactions
compared with other artificial plasma volume expanders.
There is no risk of transmission of infectious agents
compared with human plasma [3]. Rapid correction of
intravascular volume is achieved with a small infused
volume (4 ml/kg) [1].* Correspondence: mojtahed@sina.tums.ac.ir
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distribution, and reproduction in any mediumRecent studies demonstrated immunomodulatory
effects of hypertonic saline by blunting neutrophil acti-
vation and reducing cytokine production [4,5].
Cardiac surgery with cardiopulmonary bypass (CPB)
leads to acute changes in the composition and volume
of body fluid compartments. CPB dilutes serum pro-
teins, decreases the plasma colloid osmotic pressure and
reduces endothelial integrity [6]. This causes fluid shifts
from the intravascular to extravascular space and leads
to a 33% increase in extravascular fluid space and tissue
edema [7]. Complement activation following with sys-
temic inflammatory response syndrome (SIRS) occurs
during extracorporeal circulation [6]. Depending on the
severity, inflammatory response can cause cerebral, myo-
cardial, pulmonary and renal dysfunction [6].
In this study it was hypothesized that administration
of HS just before coronary artery bypass surgery (CABG)
was be helpful in decreasing of generated inflammatory
cytokines because of increasing in intravascular volume
and tissue perfusion.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Study design & Patient population: The present study is
a randomized double-blinded clinical trial. 40 patients
<70 years old, undergoing elective CABG surgery ad-
mitted in Tehran Heart Center, Tehran University of
Medical Sciences, between December 2010 & March
2011, entered into the study. Patients were randomly
assigned to control (A) and intervention (B) groups,
based on a computerized randomization sequence form.
All patients had undergo necessary clinical and para-
clinical examinations including: CBC, Diff, Electrolytes,
PFT, LFT, renal function tests, chest X ray, ECG, Car-
diac Enzyme Assay, PT, PTT, INR, thyroid tests, blood
group and matching, Carotid Doppler,. . ., patient edu-
cations, consultations, and preparing processes before
surgery.
All the perioperative cares and also surgeries were car-
ried out by the same (single) surgeon and intensivist
who were blinded to the treatment groups. Patients also
were blinded to the choice of fluids.
All patients had ejection fraction (EF) >35% and their
serum creatinine were between 0.5-1.5 mg/dl pre-
operatively. Our research was approved by Pharma-
ceutical Sciences Research Center ethics committee by
ethical code of 89-7-7:15–1 according to the declaration
of Helsinki and written informed consent was obtained
from the legal guardian of each patient before enrollment.
Exclusion criteria included any concomitant operation,
recent myocardial infarction (during 6 months), emergent
surgery, urgent or elective intubation before surgery, un-
stable hemodynamic status, recent cerebral vascular acci-
dent, neurological complications or consciousness
disorder or significant neuralgic defect, head trauma, un-
controlled diabetes mellitus, congenital heart disorder,
blood transfusion before operation, pre-operative infec-
tion, serum creatinine >1.5 mg/dl or GFR < 50, Na > 150
mmole/dl, BMI > 40 and Chronic Obstructive Pulmonary
Disease (COPD) or abnormal pulmonary function test
[respiratory distress, Carbon Dioxide Pressure (PCO2) >
45 mmHg and Oxygen Pressure (PO2) < 60 mmHg,
Forced Expiratory Volume in 1 second (FEV1) < 60% or
Forced Vital Capacity (FEV1/ FVC) < 60% and Vital
Capacity (VC) <50%].
Patients were randomized to receive 100 ml hyper-
tonic saline (5%) + 400 ml normal saline (0.9%) equiva-
lent to 155 mmole NaCl (group B) or 500 ml normal
saline (0.9%) equivalent to 77 mmole NaCl (group A); in
a uniform packages from a peripheral venous line in
upper arm during 6 hour before surgery.
All preparation and treatment measurements were
performed in a unique manner based on the attending
hospital protocols. Patients received oxazepam 10 mg/po
at the night before surgery, promethazine 25 mg/ po 1
hour before surgery, and clonidine 0.1 mg/po beforesurgery as premedication. Patients were NPO (except
medication) for 8 hour before surgery.
During surgery all patients had standard continuously
monitoring of ECG, pulse oximetery, invasive blood
pressure monitoring, non- invasive blood pressure moni-
toring, central venous pressure, end tidal capnometery,
central and peripheral temperature monitoring, bipec-
toral index, and also intermittent monitoring of arterial
blood gas, Na, K, BS, CBC, ACT test for heparin loading
& reversal. All patients received the same anesthetic
regimen and routine CPB management. Anesthesia was
induced by midazolam (0.05 mg/kg), fentanyl (5 mcg/
kg), propofol 2 mg/kg and pancuronium (0.1 mg/kg),
and was maintained with propofol infusion (10 mg/kg/h)
and additional doses of fentanyl & pancuronium.
Just after ICU admission, cuff pressure was controlled
and it has monitored every 8 hrs. The ventilator ma-
chine was set on SIMV-PSV mode (SIMV: Synchronized
Intermittent Mechanical Ventilation, PSV: Pressure Sup-
port Ventilation), based on tidal volume = 8 cc/kg of
ideal body weight, F (IMV) = 10/min, F (IMV + PSV) =
15/min, I/E (Inspiratory/Expiratory) = 1/2, PEEP (Posi-
tive End-Expiratory Pressure) = 5 cmH2O, PSV = 5
cmH2O above PEEP (total inspiratory pressure support
= 10 cmH2O), pressure support = 10 cmH2O, oxygen
flow = 60 lit/min and FiO2 =50% at first, then adjusted
based on PaO2. Subsequently ventilation was adjusted
based on ABG, and other laboratory and clinical para-
meters. Furthermore, RSBI (rapid shallow breathing
index), which is the proportion of respiratory rate/ tidal
volume, has been considered as a criteria for the extuba-
tion; if this proportion was >105, patients could not
stand the extubation. The recruitment maneuver was
done for all of patients before extubation.
Specimen collection: A 5 ml sample of blood was
obtained from each patient after receiving HS or NS, just
before operation and 24 and 48 hrs post-operatively, and
anonymously referred to local laboratory to be centri-
fuged and the serum stored at −70°C. Plasma IL-6 & IL-
10 levels were measured. We also monitored heart rate,
systolic and diastolic blood pressure, central venous
pressure, arterial pH, PaO2, FIO2, blood sugar, Na, K,
Mg, hemoglobin, white blood cell, hematocrit and plate-
let for each patient before and after surgery.
Marker measurements: Enzyme-Linked Immunosorb-
ent Assay (ELISA) technique was used to measure IL-6
(BMS213/2CE) and IL-10 (BMS215/2CE) (eBioscienceW,
Austria) samples plasma level according to manufac-
turer’s instructions.
Statistical Analysis: Data were analyzed using the stat-
istical software SPSS version 15.0 for windows (SPSS
Inc, Chicago, IL). Continuous variables are presented as
mean ± standard deviation (SD) or mean ± standard
error of mean (SEM), while categorical variables are






Number of patients 20 20
Gender (male/female) n(%) 14(70)/6(30) 11(55)/9(45) 0.270
Age (years) * 62.15 ± 7.51 61.35 ± 8.91 0.760
Weight (Kg) * 73.25 ± 11.29 69.80 ± 12.77 0.371
Height (Cm) * 166 ± 9.20 163 ± 8.58 0.301
Diabetes Mellitus n(%) 6(30) 10(50) 0.197
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Continuous variables were compared using the Student's
t-test or nonparametric Mann–Whitney U test, when-
ever the data did not appear to have normal distribu-
tions; and categorical variables were compared using
Chi-Square test, as required. Repeated measure ANOVA
was used to evaluate inter-group differences and intra-
group changes. All p values <0.05 were considered sta-
tistically significant.Unstable angina n(%) 3(15) 3(15) 0.669
Opium user n(%) 3(15) 2(10) 0.999
* Values are presented as Mean ± SD.
Result
An equal number of patients received NS or HS. There
were no differences in demographic data (Table 1).
Detailed clinical information of HS and control group
has been summarized in Table 2.
Of the 40 patients included, 4 in HS group versus 2 in
NS group had received inotropic drug within the first 24
hrs after surgery, however the different was not statisti-
cally significant (0.336) (Table 2). Plasma concentration
of sodium was nearly similar in two groups which indi-
cate that hypernatremia was not happened as a side ef-
fect of HS use. Also serum concentration of otherTable 2 Clinical Data
Variables Hy
PRE-OPERATIVE DATA
Hemoglobin (Hgb) (g/dl) *
Hematocrit (Hct) (%) *
Platelet (PLT) (n/mcL) *
White Blood Cell (WBC) (n/mcL) *
INTRA-OPERATIVE DATA
Pump Time (min) *
Cross Clamp Time (min) *
O2 Pressure (mmHg) *
Serum Bicarbonate (mmole/L) *
POST-OPERATIVE DATA
Inotrope use during first 24 h postoperative n(%)
Systolic blood pressure (SBP) <85 mmHg n (%)
Diastolic blood pressure (DBP) <70 mmHg n (%)
SBP just after anesthesia (mmHg) *
DBP just after anesthesia (mmHg) *
Heart Rate (1 h after surgery) (beat/min) *
Heart Rate (3 h after surgery) (beat/min) *
Central Vein Pressure (1 h after surgery) (cmH2O) *
Central Vein Pressure (3 h after surgery) (cmH2O) *
Intubation Duration (hr) *
Serum Sodium (Na) (mg/dl) *
Serum Potassium (K) (mg/dl) *
Serum Magnesium (Mg) (mg/dl) *
*Values are presented as Mean ± SD.electrolytes (potassium & magnesium) were not different
between two groups (Table 2).
The plasma levels of pro-inflammatory (IL-6) and
anti-inflammatory (IL-10) cytokines were significantly
changed during 48 hrs post-operatively in two groups
(p < 0.001 & p < 0.005 respectively) (Figure 1). The
mean of IL-6 levels at 24 hrs and 48 hrs post-operatively
in HS group were lower than NS group, but this differ-
ences were not statistically significant (p = 0.437). Thepertonic saline (5 %) Normal saline (0.9 %) P-value
13.93 ± 2.02 13.44 ± 1.67 0.410
40.97 ± 4.22 40.50 ± 4.22 0.727
209616.67 ± 65771 197915 ± 59753 0.57
7143 ± 1831.92 7200 ± 2045.04 0.933
56.70 ± 18.16 61.22 ± 13.61 0.397
30.36 ± 6.79 31.82 ± 7.10 0.629
221.70 ± 123.6 234 ± 107.67 0.744




108.84 ± 18.77 110 ± 10.64 0.813
63 ± 14.24 66.90 ± 10.16 0.329
85.55 ± 14.460 88.10 ± 12.039 0.548
84.90 ± 13.114 88.10 ± 10.336 0.397
11.25 ± 4.518 9.45 ± 4.186 0.199
11.25 ± 4.50 9.88 ± 4.232 0.345
14.08 ± 4.17 13.98 ± 3.80 0.943
141.45 ± 4.85 142.80 ± 3.80 0.334
4.37 ± 0.50 4.28 ± 0.44 0.531
2.08 ± 0.14 2.08 ± 0.17 0.959
Figure 1 Changes in plasma concentration of IL-6 and IL-10 for
hypertonic saline vs. normal saline by hours. Solid squares,
hypertonic saline; open circles, normal saline.








29.69 ± 7.26811 27.73 ± 14.32458 0.85
IL-6 levels 24 h
postoperatively
145.53 ± 29.80616 174.41 ± 26.89984 0.57
IL-6 levels 48 h
postoperatively
113.13 ± 18.64981 146.97 ± 24.28702 0.31
IL-10 levels right
before surgery
4.95 ± 1.24330 2.49 ± 1.10323 0.12
IL-10 levels 24 h
postoperatively
12.55 ± 3.63537 10.04 ± 2.89789 0.55
IL-10 levels 48 h
postoperatively
8.35 ± 1.97194 6.24 ± 1.62633 0.40
*Values are presented as Mean ± SEM. Values are in pg/ml.
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48 hrs post-operatively in HS group were higher than
NS group, but the mean levels between two groups were
not statistically significant (p = 0.276).
IL-6 levels rose significantly during 24 hrs in both
groups but its changes were more considerable in NS
group in comparison to HS group, while the mean level
was 145.53 pg/ml 24 hrs post-operatively in HS group
versus 174.41 pg/ml in NS group. We had a decline in
IL-6 levels between 24–48 h after surgery in two groups;
the mean level after 48 h was 113.13 pg/ml for HS group
and 146.97 pg/ml for NS group (Table 3, Figure 1). Dur-
ing the first 24 h after surgery IL-10 levels in two groups
rose from baseline and its level in HS group (mean
value: 12.55) was higher than NS group (mean value:
10.04). IL-10 levels manifested a decline 48 h after oper-
ation and mean IL-10 level was 8.35 in HS group and
6.24 in NS group. (Table 3, Figure 1).
Discussion
Patients undergoing CABG surgery with CPB, experi-
ence many aggressive factors, including operative
trauma, cardioplegia, ischemia-reperfusion injury and
the contact of blood with bioactive surfaces that poten-
tially related to a whole body inflammatory response [8].
Although this inflammatory reaction to CPB oftenremains at subclinical levels, it can also lead to import-
ant clinical implications. In 1999 the Society of Thoracic
Surgeons National Database, reported that 20% of “low-
risk” patients developed post-operative complications
[9]. Another work in these patients had shown the inci-
dence of multiple organ dysfunction syndrome (MODS)
following CPB was 11%, with a mortality rate of 41% [6].
Various studies have investigated different methods to
reduce this vigorous inflammatory response following
cardiac surgery with CPB; include perioperative adminis-
tration of corticosteroids [10], aprotinin [11], statins
[12], pentoxifylline [13], milrinone [14], ketamine [15],
and bovine intestinal alkaline phosphatase [16].
A review article by Pasnik J [17] indicates that mech-
anism of inflammatory response to CPB is due to neu-
trophil activation, degranulation and endothelial
dysfunction.
Ischemia-reperfusion injury that often occur following
aortic declamping, cause a significant elevation in
plasma cytokine levels during and after cardiac surgery
under CPB. Consequences of reperfusion injury in major
organs such as heart, lung, and central nervous system,
include myocardial stunning and alteration in beta-
receptor function (that related to transient and chronic
myocardial ischemia respectively) [18]; acute respiratory
distress syndrome (ARDS) and prolonged mechanical
ventilation [19]; delirium, encephalopathy, stroke and
cognitive brain dysfunction [20]; might infringe the clin-
ical benefit of interventions employing extracorporeal
circulation and clamping of the aorta.
HS solutions have been examined in numerous studies
as plasma volume expanders for resuscitation in various
hypovolemic situations but there is little attention to
their immunomodulatory effects. Basic science studies
have demonstrated that HS has marked effects on the
immune system. More investigations have confirmed
that HS blunted neutrophil (PMNs) activation and
diminished the monocytes production profile in patients
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reduced pro-inflammatory tumor necrosis factor (TNF)-
alpha production significantly, while increasing anti-
inflammatory IL-10, thus altering the balance between
pro-inflammatory and anti-inflammatory cytokines [4,5].
Coelho and collageous [21], demonstrated that expres-
sion of cyclooxygenase (COX)-2 and inducible nitric
oxide synthase (iNOS) was markedly increased in the
pancreas of the acute pancreatitis patients and was
reduced by treatment with HS. HS also reduced the
levels of TNF-alpha and IL-6 but not of IL-10 in the
pancreatic tissue. In another study, Coimbra and col-
lageous [22] demonstrated that HS reduce traumatic
shock induced T-cell dysfunction.
IL-6 is produced by monocytes, lymphocytes, and
endothelial cells. IL-6 induces the adhesive neutrophil-
cardiac myocyte interaction and myocardial damage
following CPB surgery. Highest plasma level of IL-6 sig-
nificantly correlated with the duration of SIRS [23] and
also outcome in other setting of SIRS positive patients
like [24-27]. Results of this study indicated anti-
inflammatory effect of pre-operative administration of
HS in patients undergoing CABG (Figure 1). IL-6
plasma levels were lower (but not statistically significant)
in HS group during 48 h after surgery. This effect may
be justified by HS osmotic effect. Osmotic effects of HS
solution resulted in fluid shift from intracellular to the
interstitial and intravascular space [1].
In the state of ischemia (duration of aortic cross
clamp) endothelial surface layer thickness and glycocalyx
structure have impaired, and dimension of glycocalyx
degradation was proportional to the duration of ische-
mia [28], therefore endothelial cell membrane ion ex-
change has disturbed and ATP loss has occurred [1].
Destruction of the glycocalyx could be a trigger for
increased trans-endothelial permeability leading to the
development of tissue edema. Pre-operative use of HS
induces normalization of endothelial cell volume and
edema that increase capillary diameter and reduce resist-
ance to flow. Therefore plasma viscosity is reduced as a
result of the plasma volume expansion [1]. Hypertonicity
has a direct relaxant effect on vascular smooth muscle
with resultant arteriolar vasodilatation [1]. Overally,
these physiological effects result in increased capillary
blood flow and this improvement observed in all areas
of microcirculation by HS [1].
After declamping aorta and reestablishing the micro-
vascular perfusion, the ischemic process has been
stopped by supplying the oxygen and nutrients, but at
the same time a cascade of events has similar character-
istics to inflammatory response is rapidly initiated. This
inflammatory-like response to ischemia-reperfusion,
mediated largely by neutrophils [29]. Stimulated poly-
morphonuclears (PMNs) via the expression of adhesionmolecules leading to interaction between endothelial
cells therefore play a critical role in extending the tissue
damage [30].
IL-10 is a prototypical endogenous anti-inflammatory
and immunosuppressive cytokine [31], which inhibits
monocyte/macrophage activation and down-regulates
the biosynthesis of TNF-α and IL-1β, while preventing
their biologic actions via up-regulation of IL-1ra [32].
IL-10 also decreases leukocyte adhesion and its recruit-
ment to sites of inflammation [31]. Together these med-
iators serve to limit the potentially injurious effects of
excessive inflammatory reactions [32]. Several recent
investigations have shown that early therapeutic admin-
istration of IL-10 is effective in preventing the initial
surge in TNF-α observed after traumatic hemorrhagic
shock [33], and also in reducing the systemic inflamma-
tory response and lethality in murine models of sepsis
and reperfusion injury [34].
Higher levels of IL-10 in HS group of our study may
indicate its ability to evoke host anti-inflammatory cyto-
kines to reduce reperfusion damage.
HS solutions have benefits on cardiac outputs, because
of the increasing preload (venous return and volume
expanding effect) and decreasing afterload (vasodilation
and reduction in pulmonary and systemic vascular re-
sistance) [1,35]. Whether cardiac output improving, be-
cause of the direct effect of HS on increasing cardiac
contractility and having inotropic effect or due to pre-
load effect must be further investigated [1,35]. In our
study we have found that patients receiving HS required
inotropic support more frequently comparing to normal
saline group (4 vs. 2 p = 0.366) in the first 24 h after sur-
gery, that may refute cardiac benefits of HS, but not sta-
tistically significant. We can explain this phenomenon,
that myocardial stunning or altering in beta-receptor
function as a result of ischemia-reperfusion injury oc-
curred in some of them. Moreover patients receiving HS
had lower systolic and diastolic pressure in comparison
with NS receiving group which can due to possible tran-
sient hypotensive effect after administration of hyper-
tonic saline, which was noted by Boldt J and collageous's
[36]. We can suggest designing another study using HS
during CPB, because in this period dropping of blood
pressure is more considerable. Looking at the positive
clinical trend of our patient’s treatment groups chal-
lenged with HS, higher dose of HS could be considered
in a larger sample size study following CABG to reach
improved statistical and clinical results.
Limited number of eligible candidate for intervention
with hypertonic saline before CABG, uni-center nature
of the study, high cost of cytokine evaluation and ethical
concern regarding the safety of hyperoncotic fluids on
subject with venerable hemodynamic profiles were mean
parts of our study’s limitations.
Mazandarani et al. DARU Journal of Pharmaceutical Sciences 2012, 20:49 Page 6 of 7
http://www.darujps.com/content/20/1/49Conclusion
Pre-treatment with small volume hypertonic saline may
have beneficial effects on inflammatory response follow-
ing CABG operation.
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